Fulcrum Therapeutics
FULC
Fulcrum Therapeutics (FULC) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Mar 31, 2026
- EPS actual
- −$0.25
- EPS estimate
- −$0.29
- EPS surprise
- +15.05%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Apr 27, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | Apr 27, 2026 | −$0.29 | −$0.25 | +15.05% | $0.00 | SEC |
| Q4 2025 | Feb 24, 2026 | −$0.30 | −$0.31 | −3.64% | $0.00 | SEC |
| Q3 2025 | Oct 29, 2025 | −$0.29 | −$0.31 | −5.51% | $0.00 | SEC |
| Q2 2025 | Jul 29, 2025 | −$0.29 | −$0.28 | +3.45% | $0.00 | SEC |
| Q1 2025 | May 1, 2025 | −$0.29 | −$0.28 | +4.76% | $0.00 | SEC |
| Q4 2024 | Feb 25, 2025 | −$0.28 | −$0.31 | −10.05% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.40 | −$0.35 | +11.68% | $0.00 | SEC |
| Q2 2024 | Jul 31, 2024 | −$0.41 | $0.87 | +311.17% | $80.0M | SEC |
| Q1 2024 | May 13, 2024 | −$0.44 | −$0.43 | +1.71% | $0.00 | SEC |
| Q4 2023 | Feb 27, 2024 | −$0.43 | −$0.40 | +6.04% | $871,000.00 | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.44 | −$0.39 | +11.50% | $759,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.45 | −$0.38 | +16.26% | $880,000.00 | SEC |
| Q1 2023 | May 15, 2023 | −$0.46 | −$0.41 | +11.47% | $295,000.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$0.49 | −$0.50 | −2.06% | $685,000.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.61 | −$0.51 | +16.69% | $1.2M | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.66 | −$0.83 | −25.62% | $1.9M | SEC |
| Q1 2022 | May 9, 2022 | −$0.63 | −$0.64 | −2.09% | $2.6M | SEC |
| Q4 2021 | Mar 3, 2022 | −$0.73 | −$0.58 | +20.27% | $5.1M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.65 | −$0.57 | +11.91% | $4.9M | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.65 | −$0.60 | +8.05% | $4.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Fulcrum Therapeutics (FULC) last report earnings?
Fulcrum Therapeutics last reported on Apr 27, 2026, covering fiscal Q1 2026.
Did FULC beat earnings estimates?
Yes. Fulcrum Therapeutics reported EPS of −$0.25 for Q1 2026 against a −$0.29 estimate — a 15.05% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.